mark lowdell

He is consultant to or founder of many of the key companies involved in Advanced Therapy Medicinal Products (ATMP) development in the EU and USA, including INmuneBio Inc. (NASDAQ: INMB), for which he acts as Chief Scientific Officer.  

He established the first academic GMP facility in the UK for the production of human cells as medicines in 2003. Mark holds MHRA Qualified Person status for the release of ATMPs for clinical trials. This facility now produces somatic cell medicines, gene therapies and tissue engineered products and is particularly adept at developing processes for scale-up of ATMP production. His ATMP GMP suite at RFH / UCL consists of 12 state-of-the-art manufacturing labs supporting multiple academic and commercial trials of somatic cell and tissue engineered therapies. 

Much of his career has focused on adoptive immunotherapy of cancer and has targeted the role of the innate immune responses; especially the role of natural killer (NK) cells, although his experience includes a variety of adoptive T cell therapies (cancer and viral infection) as well as dendritic cell vaccines and CAR T-cells.